← GRAIL, LLC overview

GRAIL, LLC vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GRAIL, LLC (GRAL)

Q3 2026
▲2▼1

FDA Panel Backs Galleri, but Fraud Lawsuits Loom

  • FDA Panel Endorses Galleri An FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 that benefits outweigh risks. This clears a major hurdle toward expected early-2027 approval and potential Medicare and private insurance coverage.

    This is the biggest new positive catalyst that could drive future revenue and stock price.

  • Strong Sales and Samsung Investment Q2 Galleri volume rose 35% to over 61,000 tests, revenue grew 24% to $42.6 million, and total revenue rose 26% to $44.7 million. Samsung's $110 million equity investment strengthened the balance sheet.

    These new financial and strategic developments show improving business performance and cash position.

  • Securities Fraud Lawsuits Pile Up Lawsuits over alleged misstatements about the failed NHS-Galleri trial kept accumulating, raising legal costs and negative attention. The August 4 lead plaintiff deadline sustained pressure, creating a legal overhang that could weigh on the stock.

    This ongoing legal risk is a key negative factor that could result in penalties and distract management.

August 2026
▲2▼1

FDA Panel Backs Galleri, but Securities Fraud Lawsuits Loom

  • FDA Panel Endorses Galleri On September 24, an FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 benefits outweigh risks. This clears a major hurdle toward FDA approval, expected early 2027, which would open Medicare and private insurance coverage and boost future sales.

    This is the biggest new positive catalyst, directly advancing the path to insurance coverage and revenue growth.

  • Strong Q2 Galleri Volume and Revenue Growth GRAIL reported Q2 2026 Galleri test volume up 35% to over 61,000 and revenue up 24% to $42.6 million. Total revenue rose 26% to $44.7 million, and a $110 million equity investment from Samsung strengthened the balance sheet, showing growing demand and financial backing.

    This new data confirms commercial momentum and cash strength, supporting the stock's fundamental value.

  • Securities Fraud Lawsuits Over Trial Disclosures Multiple law firms filed or reminded investors of a securities class action alleging GRAIL misled investors about the NHS-Galleri trial's likelihood of success. The August 4 lead plaintiff deadline passed, but the lawsuit continues, creating legal overhang and potential financial penalties that could weigh on the stock.

    This is a new legal development that adds uncertainty and potential costs, a real counterweight to the positive news.

Latest
▲2▼1

FDA Panel Backs Galleri, but Securities Fraud Lawsuits Loom

  • FDA Panel Endorses Galleri On September 24, an FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 benefits outweigh risks. This clears a major hurdle toward FDA approval, expected early 2027, which would open Medicare and private insurance coverage and boost future sales.

    This is the biggest new positive catalyst, directly advancing the path to insurance coverage and revenue growth.

  • Strong Q2 Galleri Volume and Revenue Growth GRAIL reported Q2 2026 Galleri test volume up 35% to over 61,000 and revenue up 24% to $42.6 million. Total revenue rose 26% to $44.7 million, and a $110 million equity investment from Samsung strengthened the balance sheet, showing growing demand and financial backing.

    This new data confirms commercial momentum and cash strength, supporting the stock's fundamental value.

  • Securities Fraud Lawsuits Over Trial Disclosures Multiple law firms filed or reminded investors of a securities class action alleging GRAIL misled investors about the NHS-Galleri trial's likelihood of success. The August 4 lead plaintiff deadline passed, but the lawsuit continues, creating legal overhang and potential financial penalties that could weigh on the stock.

    This is a new legal development that adds uncertainty and potential costs, a real counterweight to the positive news.

July 2026
▼2

GRAIL's Legal Overhang Deepens as August 4 Deadline Nears

  • Securities Fraud Lawsuits Keep Piling Up Multiple law firms have filed or are investigating securities fraud claims against GRAIL over the failed NHS-Galleri trial. The growing number of suits raises potential legal costs and keeps negative attention on the stock, weighing on the share price.

    This is the main new development this period, with several firms joining and a key deadline approaching.

  • August 4 Lead Plaintiff Deadline Looms Investors have until August 4, 2026 to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the news and may prompt more shareholders to come forward, sustaining pressure on GRAIL's stock.

    The deadline is a specific upcoming event that could drive further negative headlines and investor anxiety.

▼2

GRAIL's Legal Overhang Deepens as August 4 Deadline Nears

  • Securities Fraud Lawsuits Keep Piling Up Multiple law firms have filed or are investigating securities fraud claims against GRAIL over the failed NHS-Galleri trial. The growing number of suits raises potential legal costs and keeps negative attention on the stock, weighing on the share price.

    This is the main new development this period, with several firms joining and a key deadline approaching.

  • August 4 Lead Plaintiff Deadline Looms Investors have until August 4, 2026 to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the news and may prompt more shareholders to come forward, sustaining pressure on GRAIL's stock.

    The deadline is a specific upcoming event that could drive further negative headlines and investor anxiety.

Q2 2026
▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

June 2026
▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

  • Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.

    Strong financial results directly boost investor confidence and the stock price.

  • Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.

    This major setback significantly impacted Regeneron's market value and reputation.

  • Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.

    The deal has both positive financial aspects and negative implications for Dupixent economics.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 2026
▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

© 2026 MarketIVWhy